{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:09:12Z","timestamp":1762272552714,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.04.074","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T17:43:16Z","timestamp":1589305396000},"page":"4374-4378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines"],"prefix":"10.1016","volume":"38","author":[{"given":"Olof","family":"S\u00e4ll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2020.04.074_b0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","article-title":"Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination","volume":"15","author":"Burman","year":"2019","journal-title":"Human Vacc Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.074_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/eri.13.42","article-title":"The burden and impact of severe and long-term sequelae of meningococcal disease","volume":"11","author":"Vyse","year":"2013","journal-title":"Expert Rev Anti-infective Therapy"},{"issue":"21","key":"10.1016\/j.vaccine.2020.04.074_b0015","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.04.074_b0020","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/14760584.2015.979799","article-title":"Evolving meningococcal immunization strategies","volume":"14","author":"Safadi","year":"2015","journal-title":"Expert Rev Vacc"},{"issue":"5","key":"10.1016\/j.vaccine.2020.04.074_b0025","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/21645515.2018.1451810","article-title":"Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development","volume":"14","author":"Dretler","year":"2018","journal-title":"Human Vacc Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2020.04.074_b0030","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"5","key":"10.1016\/j.vaccine.2020.04.074_b0035","article-title":"Recent Progress in the Prevention of Serogroup B Meningococcal Disease","volume":"24","author":"Feavers","year":"2017","journal-title":"Clin Vacc Immunol CVI"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.074_b0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae)","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.vaccine.2020.04.074_b0045","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2020.04.074_b0050","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"unstructured":"European Commission. Commission implementing decision of 8 August 2012 amending decision 2002\/253\/EC laying down case definitions for reporting communicable diseases to the community network under decision no. 2119\/98\/EC of the European Parliament and of the Council (notified under document C(2012) 5538): text with EEA relevance (2012\/506\/EU) 2012. https:\/\/publications.europa.eu\/en\/publication-detail\/-\/publication\/10ed460f-0711-11e2-8e28-01aa75ed71a1\/language-en; 2012 [accessed 14 April 2020].","key":"10.1016\/j.vaccine.2020.04.074_b0055"},{"issue":"11","key":"10.1016\/j.vaccine.2020.04.074_b0060","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2020.04.074_b0065","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2020.04.074_b0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2020.04.074_b0075","article-title":"Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine","volume":"24","author":"Lujan","year":"2017","journal-title":"Clin. Vacc Immunol. CVI."},{"issue":"23","key":"10.1016\/j.vaccine.2020.04.074_b0080","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine."},{"issue":"9960","key":"10.1016\/j.vaccine.2020.04.074_b0085","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.vaccine.2020.04.074_b0090","doi-asserted-by":"crossref","first-page":"e027233-e","DOI":"10.1136\/bmjopen-2018-027233","article-title":"Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis","volume":"9","author":"Marshall","year":"2019","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.074_b0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.vaccine.2020.04.074_b0100","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2452","article-title":"Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab","volume":"140","author":"Parikh","year":"2017","journal-title":"Pediatrics"},{"issue":"27","key":"10.1016\/j.vaccine.2020.04.074_b0105","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.074_b0110","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:08Z","timestamp":1759401788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20305910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":22,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20305910"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.074","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}